Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MOR106 single ascending doses
MOR106 · 1 trial · 2 indications
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
To evaluate the safety and tolerability of single ascending doses of MOR106 intravenously given to healthy male subjects and of multiple ascending doses of MOR106 given intravenously to subjects with atopic dermatitis, compared to placebo
| Arm | Type | Description |
|---|---|---|
| MOR106 | EXPERIMENTAL | Single intravenous administration of MOR106 |
| Placebo | PLACEBO_COMPARATOR | Single intravenous administration of Placebo |
| MOR106 MAD | EXPERIMENTAL | Multiple intravenous administration of MOR106 |
| Placebo MAD | PLACEBO_COMPARATOR | Multiple intravenous adminstration of Placebo |
| Name | Type | Description |
|---|---|---|
| MOR106 single ascending doses, intravenous | DRUG | - |
| Placebo single ascending doses, intravenous | DRUG | - |
| MOR106 multiple ascending doses, intravenous | DRUG | - |
| Placebo multiple intravenous administrations | DRUG | - |
Inclusion Criteria: \- Able and willing to give voluntary written informed consent Single ascending dose (SAD) * Negative urine drug screen * Male between 18-50 years of age * A body mass index (BMI) between 18-30 kg/m², inclusive. * Judged to be in good health Multiple ascending dose (MAD) * M...
MOR106 is an investigational small molecule developed by Lakefront Biotherapeutics for atopic dermatitis, a form of eczema. It has been studied in a Phase 1 first-in-human trial that enrolled 81 participants, including healthy volunteers and people with atopic dermatitis. MOR106 is not approved and remains in clinical development.
MOR106 is being developed for the treatment of atopic dermatitis, a chronic inflammatory skin condition. Its clinical testing has focused on this dermatology indication, with a Phase 1 trial that included participants with atopic dermatitis alongside healthy volunteers. It is investigational and has not been approved for any use.
MOR106 is developed by Lakefront Biotherapeutics, which trades under the ticker LKFT. The company is the sponsor of the drug's clinical program in atopic dermatitis.
MOR106 is in Phase 1 development. Its only recorded trial, NCT02739009, was a Phase 1 first-in-human study that has been completed. The drug is investigational and has not received regulatory approval.
MOR106 has been evaluated in one clinical trial, NCT02739009, titled First in Human of Single and Multiple Doses of MOR106. This completed Phase 1 study enrolled 81 participants across Belgium, Hungary, Moldova, and Romania and included healthy volunteers and patients with atopic dermatitis.
Yes. MOR106 single ascending doses, intravenous and MOR106 single ascending doses are alternative names used for MOR106, the investigational small molecule from Lakefront Biotherapeutics being studied in atopic dermatitis. These names refer to the same drug asset and its Phase 1 clinical program.